Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2005-07-05
2005-07-05
Nickol, Gary B. (Department: 1642)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C424S094200, C424S094620, C424S094670
Reexamination Certificate
active
06913744
ABSTRACT:
A method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase and at least one of a glycosidase, a protease, a nuclease, a lipase, an esterase, a plasminogen activator, a streptokinase, and combinations thereof. Preferably a glycosidase, such as, for example, hyaluronidase, is administered. Compositions used in methods for treating prostate cancer can also include or be administered with calcium ions, a nonionic surfactant, such as, for example, Triton® X-100, and an antibiotic, such as, for example, gentamicin. Another method of treating prostate cancer in a living mammal includes activating PSA in vivo by, for example, locally administering calcium ions.
REFERENCES:
patent: 4524065 (1985-06-01), Pinnell
patent: 4645668 (1987-02-01), Pinnell
patent: 4678668 (1987-07-01), Darras
patent: 4978332 (1990-12-01), Luck et al.
patent: 5051257 (1991-09-01), Pietronigro
patent: 5116615 (1992-05-01), Gokcen et al.
patent: 5162115 (1992-11-01), Pietronigro
patent: 5422261 (1995-06-01), Lee et al.
patent: 5424208 (1995-06-01), Lee et al.
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5658730 (1997-08-01), McGill et al.
patent: 5753485 (1998-05-01), Dwulet et al.
patent: 5780435 (1998-07-01), Garnick et al.
patent: 5783182 (1998-07-01), Thompson
patent: 5830741 (1998-11-01), Dwulet et al.
patent: 5843902 (1998-12-01), Garnick et al.
patent: 5854206 (1998-12-01), Twardzik et al.
patent: 5952215 (1999-09-01), Dwulet et al.
patent: 5989888 (1999-11-01), Dwulet et al.
patent: WO 90/08555 (1990-08-01), None
patent: WO 97/10842 (1997-03-01), None
Murphy et al., Clinical Oncology, 2nd edition, American Cancer Society, 1995, pp. 315-318.
Baert, L, et al., “Treatment of Chronic Bacterial Prostatitis by Local Injection of Antibiotics into Prostate”,Urology, vol. XXL, No. 4, pp. 371-375 (Apr. 1983).
Cawston, T. et al., “Mammalian Collagenases”,Methods in Enzymology, vol. 80, pp. 711-722 (1981).
Chang, N., “Transforming Growth Factor-Beta Protection of Cancer Cells Against Tumor Necrosis Factor Cytotoxicity is Counteracted by Hyaluronidase”,J. Mol. Med., vol. 2, No. 6, pp. 653-659 (Dec. 1998) (Abstract Only).
Darson, M. et al., “Transurethral Enzyme Injection—Future Management of Benign Prostatic Hyperplasia”,Mayo Clin Proc, vol. 73, pp. 908-911 (1998).
Giovannucci, E. et al., “Calcium and Fructose Intake in Relation to Risk of Prostate Cancer”,Cancer Research, vol. 58, pp. 442-447 (Feb. 1, 1998).
Harmon, W. et al., “Transurethral Enzymatic Ablation of the Prostate: Canine Model”,Urology, vol. 48, No. 2, pp. 229-233 (Aug. 1996).
Liu , A. et al., “Cell-cell Interaction in Prostate Gene Regulation and Cytodifferentiation”,Proc. Natl. Acad. Sci. USA, vol. 94, No. 20, pp. 10705-10710 (Sep. 30, 1997).
Lokeshwar, V. et al., “Association of Elevated Levels of Hyaluronidase, a Matrix-degrading Enzyme, with Prostate Cancer Progression”,Cancer Res., vol. 56, No. 3, pp. 651-657 (Feb. 1, 1996) (Abstract Only).
Longo, F. et al., “Collagenase as an Adjunct to Cryoprostatectomy”,Collagenase, Editor: I. Mandl,, Gordon & Breach, New York, New York, pp. 113-120 (1972).
Marieb, E.,Human Anatomy and Physiology, Second Edition, The Benjamin/Cummings Publishing Company, Inc., p. 936, (1992).
Nagle, R. et al., “Adhesion Molecules, Extracellular Matrix, and Proteases in Prostate Carcinoma”,Journal of Cellular Biochemistry, Supplement 19, pp. 232-237 (1994).
Partsch, G. et al., “High Free and Latent Collagenase Activity in Psoriatic Arthritis Synovial Fluids”,British Journal of Rheumatology, vol. 33, No. 8, pp. 702-706 (Aug. 1994).
Presnell, S. et al., “Isolation and Characterization of Propagable Cell Lines (HUNC) from the Androgen-sensitive Dunning R3327H Rat Prostatic Adenocarcinoma”,Carcinogenesis, vol. 19, No. 4, pp. 585-590 (Apr. 1998).
Saltus, R., “The Answer for Cancer?”,Popular Science, pp. 52-55 (Jan. 1999).
Sehgal, I. et al., “Transforming Growth Factor Beta1 Stimulates Contrasting Responses in Metastatic Versus Primary Mouse Prostate Cancer-derived Cell Lines in Vitro”,Cancer Res., vol. 56, No. 14, pp. 3359-3365 (Jul. 15, 1996) (Abstract Only).
VanDeGraff, K. et al.,Concepts of Human Anatomy and Physiology, Wm. C. Brown Publishers, p. 938 (1986).
“NCI Publication—What You Need To Know About (tm) Prostate Cancer”, http://cancernet.nci.nih.gov/wyntk_pubs/prostate.htm, 25 pages (Dec. 12, 2000).
“Prostate Cancer”, http://www.cancerpage.com/articles/default.asp?id=3&subarea=Your_Illness, 4 pages (Nov. 9, 2000).
“Prostate Enlargement: Benign Prostatic Hyperplasia”, http://www.niddk.nih.gov/health/urolog/pubs/prostate/index.htm, 15 pages (Jan. 2000).
Immunolytics Inc.
Merchant & Gould P.C.
Nickol Gary B.
LandOfFree
Method and composition for treating prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for treating prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treating prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3427613